Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nanoviricides Inc (NY: NNVC )

1.110 -0.040 (-3.48%)
Official Closing Price Updated: 4:00 PM EDT, Jun 9, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 24,215
Open 1.250
Bid (Size) 1.040 (30)
Ask (Size) 1.180 (6)
Prev. Close 1.150
Today's Range 1.110 - 1.250
52wk Range 1.040 - 3.880
Shares Outstanding 11,666,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The 7 Most Promising Penny Stocks to Buy in June
These top penny stocks for June look to have legitimate catalysts that can certainly send share prices higher. 
Via InvestorPlace
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga

Performance

YTD
-1.77%
-1.77%
1 Month
-13.28%
-13.28%
3 Month
-18.38%
-18.38%
6 Month
-23.45%
-23.45%
1 Year
-45.85%
-45.85%

More News

Read More
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
NanoViricides, Inc. to Present at the BIO International Convention in Boston on June 5th, 2023 at 3:15pm ET
Via ACCESSWIRE
NanoViricides Has Filed its Quarterly Report - Clinical Trials of Broad-Spectrum COVID Drug About to Begin
Via ACCESSWIRE
COVID Remains A Global Threat – NanoViricides Set To Begin Clinical Trials For Pan-Coronavirus Drug To Help Defeat COVID Once And For All
Via TheNewswire.com
Exposures COVID-19
TechMediaBreaks – NanoViricides Inc. (NYSE American: NNVC) Slated to Participate at Inaugural Ef Hutton Global Conference
Via Investor Brand Network
Exposures COVID-19
NanoViricides, Inc. (NYSE American: NNVC) Featured in Coverage of the Inaugural EF Hutton Global Conference
Via Investor Brand Network
Exposures COVID-19
NanoViricides is Expanding its Broad-Spectrum Antiviral Program to Explore Further Antiviral Applications of its COVID Clinical Drug Ingredient
Via ACCESSWIRE
NanoViricides Has Shipped Drug Products for Impending Clinical Trials of NV-CoV-2, Its COVID Drug Candidate
Via ACCESSWIRE
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
NanoViricides Signs a License Agreement That Includes Clinical Evaluation of Its COVID-19 Drug Candidates
Via ACCESSWIRE
COVID Remains A Global Threat – NanoViricides Set To Begin Clinical Trials For Pan-Coronavirus Drug To Help Defeat COVID Once And For All
Via News Direct
Exposures COVID-19
A Company With Solutions Against Emerging COVID Variants And Other Viral Infections To Combat Future Pandemic Threats
Via News Direct
Topics Death Economy
Exposures COVID-19 Death Economy
A Company With Solutions Against Emerging COVID Variants And Other Viral Infections To Combat Future Pandemic Threats
Via TheNewswire.com
Topics Death Economy
Exposures COVID-19 Death Economy
With Nearly 20,000 Americans Still Hospitalized, COVID Remains A Threat – NanoViricides Gets Ready To Begin Clinical Trials For The World To Defeat It
Via News Direct
Topics Death
Exposures COVID-19 Death
With Nearly 20,000 Americans Still Hospitalized, COVID Remains A Threat – NanoViricides Gets Ready To Begin Clinical Trials For The World To Defeat It
Via TheNewswire.com
Topics Death
Exposures COVID-19 Death
With Nearly 20,000 Americans Still Hospitalized, COVID Remains A Threat – NanoViricides Gets Ready To Begin Clinical Trials For The World To Defeat It, And To Prepare For Battling Against The Next Likely Coronavirus Pandemic
Via Benzinga
uniQure To Rally Around 162%? Here Are 10 Other Analyst Forecasts For Tuesday
Via Benzinga
NanoViricides Has Filed its Quarterly Report - Company has Begun Production of Coronavirus Drug for Clinical Trials
Via ACCESSWIRE
NanoViricides, Inc. to Present at the Biotech Showcase(TM) 2023 Conference in San Fransisco on January 9th at 10:30am PT
Via ACCESSWIRE
NanoViricides, Inc. to Present at the RHK Capital Disruptive Growth Conference in New York City on December 6th at 1:20pm ET
Via ACCESSWIRE
Chronic Obstructive Pulmonary Disease (COPD) Market Expected to Reach $25 Billion By 2027
Via FinancialNewsMedia
NanoViricides, Inc. Has Filed its Quarterly Report: Coronavirus Drug NV-CoV-2 IND Stage
Via ACCESSWIRE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.